High expression of FGD3, a putative regulator of cell morphology and motility, is prognostic of favorable outcome in multiple cancers

Scooter Willis, Yuliang Sun, Mark Abramovitz, Teng Fei, Brandon Young, Xiaoqian Lin, Min Ni, Justin Achua, Meredith M. Regan, Kathryn P. Gray, Robert Gray, Victoria Wang, Bradley Long, Roswitha Kammler, Joseph A. Sparano, Casey Williams, Lori J. Goldstein, Roberto Salgado, Sherene Loi, Giancarlo PruneriGiuseppe Viale, Myles Brown, Brian Leyland-Jones

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Purpose Identification of single-gene biomarkers that are prognostic of outcome can shed new insights on the molecular mechanisms that drive breast cancer and other cancers. Methods Exploratory analysis of 20,464 single-gene messenger RNAs (mRNAs) in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) discovery cohort indicates that low expression of FGD3 mRNA is prognostic for poor outcome. Prognostic significance of faciogenital dysplasia 3 (FGD3), SUSD3, and other single-gene proliferation markers was evaluated in breast cancer and The Cancer Genome Atlas (TCGA) cohorts. Results A meta-analysis of Cox regression of FGD3 mRNA as a continuous variable for overall survival of estrogen receptor (ER)-positive samples in METABRIC discovery, METABRIC validation, TCGA breast cancer, and Combination Chemotherapy in Treating Women With Breast Cancer (E2197) cohorts resulted in a combined hazard ratio (HR) of 0.69 (95% CI, 0.63 to 0.75), indicating better outcome with high expression. In the ER-negative samples, the combined meta-analysis HR was 0.72 (95% CI, 0.63 to 0.82), suggesting that FGD3 is prognostic regardless of ER status. The potential of FGD3 as a biomarker for freedom from recurrence was evaluated in the Breast InternationalGroup1-98(BIG1-98; Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer) study (HR, 0.85; 95% CI, 0.76 to 0.93) for breast cancer-free interval. In the Hungarian Academy of Science (HAS) breast cancer cohort, splitting on the median had an HR of 0.49 (95% CI, 0.42 to 0.58) for recurrence-free survival. A comparison of the Stouffer P value in five ER-positive cohorts showed that FGD3 (P = 3.8E-14) outperformed MKI67 (P = 1.06E-8) and AURKA (P = 2.61E-5). A comparison of the Stouffer P value in four ER-negative cohorts showed that FGD3 (P = 3.88E-5) outperformed MKI67 (P = .477) and AURKA (P = .820).

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalJCO Precision Oncology
Volume2017
Issue number1
DOIs
StatePublished - 2017

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'High expression of FGD3, a putative regulator of cell morphology and motility, is prognostic of favorable outcome in multiple cancers'. Together they form a unique fingerprint.

  • Cite this

    Willis, S., Sun, Y., Abramovitz, M., Fei, T., Young, B., Lin, X., Ni, M., Achua, J., Regan, M. M., Gray, K. P., Gray, R., Wang, V., Long, B., Kammler, R., Sparano, J. A., Williams, C., Goldstein, L. J., Salgado, R., Loi, S., ... Leyland-Jones, B. (2017). High expression of FGD3, a putative regulator of cell morphology and motility, is prognostic of favorable outcome in multiple cancers. JCO Precision Oncology, 2017(1), 1-13. https://doi.org/10.1200/PO.17.00009